NDAORALCAPSULE
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
adults, for the treatment of depressive episodes associated with bipolar depression (as monotherapy or as adjunctive therapy with lithium or valproate), and as adjunctive therapy with antidepressants for the treatment of MDD is unknown. However, the mechanism of action of lumateperone for these…
Pharmacologic Class:
Atypical Antipsychotic
Indications (2)
Loss of Exclusivity
LOE Date
Dec 10, 2040
179 months away
Patent Expiry
Dec 10, 2040
Exclusivity Expiry
Nov 5, 2028